

THROMBOSIS UK
(A Company Limited by Guarantee)
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2024

Registered Charity No: 1090540

Company No: 4354472

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

REFERENCE AND ADMINISTRATION DETAILS:

TRUSTEE AND MANAGEMENT

Trustees

Andrea Louise Croft

Dr Matthew Robert Fay

Professor Ian Maxwell Franklin

Simon Hart

Professor Beverley Jane Hunt OBE

Stephan Jaglin

Professor Simon Noble

Robin Offord

Dr Dalia Dawoud – Resigned 11/09/2023

Janet Morgan – Appointed 01/09/2023

Nusaiba Masnurah – Appointed 01/09/2023

CEO

Jo Jerome

Secretary

Professor Beverley Jane Hunt OBE

REGISTERED OFFICE

Couch Bright King & Co

2 Tolherst Court

Turkey Mill Business Park

Ashford Road, Maidstone

Kent ME14 5SF

AUDITORS

Couch Bright King & Co

Chartered Accountants

2 Tolherst Court

Turkey Mill Business Park

Ashford Road, Maidstone

Kent ME14 5SF

SOLICITORS

Stone King

28 Ely Place

London

EC1N 6TD

BANKERS

National Westminster Bank PLC

Maida Vale

Elgin Avenue

127 Kilburn Road

London

NW6 6JL

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

The Trustees present their annual report together with the financial statements of the charity for the year ended 31st January 2024. The financial statements have been prepared in accordance with the accounting policies set out on pages 16 to 17 and comply with the Charities Act 2011, The Statement Recommended Practice applicable to charities preparing their accounts in accordance with the Memorandum and Articles of Association, Accounting and Reporting: Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland published October 2019 and the Companies Act 2006. The report and statements also comply with the Companies Act 2006 as Thrombosis UK was incorporated by guarantee on 16th January 2002. It has no share capital and is a registered charity (registered 12th February 2002).

OBJECTIVES AND STRATEGIES

Thrombosis UK was established to advance medical science in relation to the diagnosis, causes, prevention, alleviation, management, and cure of thrombosis and for the promotion of knowledge and public education of the understanding and awareness of thrombosis. Using the powers conferred by the Memorandum of Association, Thrombosis UK aims to fund:

- A range of studies looking at why and how a thrombosis occurs.
- Research into the management and the improvement of current treatments available.
- An education program that informs people about the causes, effects, prevention, and recommended management of thrombosis.
- Provide a network of support for those affected by thrombosis.

ORGANISATION AND STRUCTURE

The Board of Trustees, who are also Directors of the company, govern Thrombosis UK.

The Trustees have the power to appoint, and remove any member, any member to act as Secretary to the Charity and all vote on the appointment of the Chair, Treasurer, and other Honorary Officers.

The charity seeks to ensure Trustees are appointed to fulfil the changing and on-going needs of the charity's activities and outcome[s]. A Trustee job description is agreed when vacancies become available to ensure existing and new Trustees have clarity on their roles and they each bring skills that complement and benefit Thrombosis UK.

New Trustees are appointed with the unanimous approval of existing Trustees. All Trustees give freely of their time and expertise and receive no remuneration for their work.

The day-to-day administration of the Charity is the responsibility of the Chief Executive Officer employed on a 0.8 permanent FTE contract. The Charity also employs a Patient Support and Helpline Lead on a 0.8 permanent contract and an Admin and Fundraising Administrator on a 0.6 permanent contract for the year under review. In 2022 the Charity appointed a Clinical Psychologist on a 0.5 two-year FTE contract starting 1st February 2022. Following review, this was extended in January 2024 for a further two years until 31st January 2026.

AIMS AND ACTIVITIES

The Charity aims to promote greater awareness and understanding of venous thromboembolism (VTE) to improve:

- Prevention of avoidable blood clots.
- Timely detection and prompt diagnosis of VTE.
- Appropriate management that improves patient outcomes.
- Timely support and education to enable patients to restore their well-being and health.

To support achievement of this, the Charity concentrates on three key areas.

- Awareness
- Education
- Research

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

Executive Summary

Thrombosis UK continues to rise to the challenge of improving awareness, education and research into venous thromboembolism. 2023 saw continued high death rates, particularly following hospital stays, which underline the urgency of improving care for this much-misunderstood condition.

The charity has continued to innovate, building on the success of previous years to record successes including:

- Responding to the lack of quality patient information to design and launch the Let's Talk Clots app to provide free and up to date support.
- Revealing the failure to meet national VTE prevention standards through FOIs to NHS Trusts.
- Securing more than a quarter of a million pounds to lead a national prevention initiative in primary care, which has already outstripped initial predictions for engagement.
- Enabling patients to access world-class care through the REGAIN study, illuminating the under-appreciated impact of thrombosis on mental health post-pandemic, and setting a standard for future interventions.
- Running an online conference with record attendance from medical professionals.

AWARENESS

Thrombosis UK has continued to raise awareness of venous thromboembolism (VTE) across multiple areas including:

- General awareness of risks, signs and symptoms.
- Impact of a VTE on individuals, and benefit of support, information and good communication.
- Failures in VTE prevention, delayed diagnosis, management and access to appropriate care and expertise.

Our annual awareness week, 'National Thrombosis Week' (NTW) held in May 2023, secured media coverage in local and national newspapers, including an interview on Sky News, reaching approximately eight million viewers.

The charity's social media platforms have also grown in followers and with support from a newly appointed Trustee, a more robust media plan is being developed to improve regular reach and engagement on the many areas of work Thrombosis UK is involved with.

Continuing our work to raise awareness of concerns in VTE prevention, in February 2023, we carried out a Freedom of Information (FOI) request to all NHS Hospital Trusts seeking information on each Trust's current policy for VTE risk assessment on all patients admitted to hospital. Due to the COVID pandemic, national reporting of VTE risk assessment rates was suspended and despite a return to pre-pandemic systems, reporting of VTE risk assessment data has not been reinstated. Thrombosis UK is aware that post pandemic the NHS is operating with increased pressures on staffing, costs, waiting lists and resources. Trusts are working to find a 'new normal' while facing extensive challenges in demand, budgets and staffing. We were concerned from discussions with multiple healthcare professionals that rates of VTE assessment have slipped without national monitoring systems in place.

We had previously carried out a Freedom of Information request to NHS Statistics to obtain NHS Digital data for Patient Outcomes Indicators for deaths due to VTE related events within 90 days of discharge from hospital, which had not been published since the Covid-19 pandemic. Prior to the pandemic between 2014/15 – 2018/19, NHS Digital data showed deaths related to VTE events within 90 days of discharge from hospital had declined. In the year from April 2018/19 there were 11,696 deaths which increased to 16,379 in the year from April 2020 to March 2021, the excess probably attributable to the increased rates of PE described in those hospitalised with Covid-19 during the pandemic, due to immunothrombosis being misinterpreted as small PEs. However, worryingly, in the year from April 2021 to March '22, deaths were still at the increased level of 14,873, reverting the previous downward trend in deaths related to VTE events shown in NHS Digital data between 2014-2019. Thrombosis UK was concerned that this continuing increased death rate might relate, at least partially, to deteriorating VTE risk assessment.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

The FOI was sent to 170 NHS Acute Trusts between February and March 2023 asking three questions about VTE prevention:

- Q1. Does the Trust routinely meet the 95% VTE Risk Assessment (RA) level required by NIS England?
- Q2. Please provide VTE RA data for each month between Jan 2022-December 2022 respectively.
- Q3. Does the Trust have dedicated funding for a team ensuring VTE prevention occurs?

Findings:

- Q1:
 - 54 Trusts responded to this question with, 'yes' or 'mostly' however,
 - Only 45 of the Trusts responding, 'yes' or 'mostly,' provided data in Q2 that evidenced 95% VTE RA level was being routinely achieved.
- Q2: Replies were received from 135 of 170 NHS England Acute and Foundation Trusts (79%).
 - Seven (5%) had suspended data collection.
 - Nine (7%) were unable to access data due to cost implications or IT issues.
 - Eight (6%) replied but did not provide data.
 - 111 (82%) provided VTE RA data.

Further information for Q2:

- 45 of the 111 (41%) routinely attained 95% VTE RA levels for 11+ months in 2022.

Of the remaining 66 (59%) Trusts during 2022:

- Nine (8%) attained 95% VTE risk assessment rates for 8-10 months.
- Four (4%) for seven months.
- 53 (48%) achieved 95% VTE risk assessment rates in six months or less, and of these
- 38 (34%) did not achieve 95% VTE RA rate in any month during 2022.

- Q3: 117 responses on dedicated funding for VTE prevention teams, were received, and have been categorised as follows:
 - 66 (56%) replying 'No'.
 - 50 (43%) indicating 'Yes'.
 - One (0.9%) indicating an unfunded role.

Analysis of Q3 responses showed that funding or identifying roles to oversee VTE prevention did not relate to VTE risk assessment rates.

Failure to prevent VTE leads to worse health outcomes and avoidable costs

Over 10% of deaths in hospital are related to hospital-acquired VTE (HA-VTE). Autopsy studies have shown that many VTEs are missed prior to death, with HA-VTE causing significant events up to 90 days post-discharge. In the current funding and staffing climate, healthcare needs to be delivered as efficiently and effectively as possible. A major factor in achieving this is implementation of a proven and effective prevention programme which should be adopted by all NHS providers.

Progress made in NHS England between 2010-2020 evidenced that a systematic approach to preventing HA-VTE was effective. Together, the VTE Prevention programme and regular publication of data underlined the benefit to patient safety, improved outcomes and achieved a reduction in burden of preventable VTE in the NHS.

Whilst reducing burden of administrative work on already over-stretched NHS teams, may be well intended, in an era when the NHS is under perhaps its greatest pressures, suspension of the collection of central VTE risk assessment data appears to be resulting in reduced priority being given to identifying those at risk of VTE and consequently being able to appropriately reduce that risk. In short, **VTE risk assessment has fallen, and death associated with VTE within 90 days of discharge, has risen.**

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

Impact of Thrombosis UK's FOI

Our work on this FOI is providing greater awareness and information to assist NHS Patient Safety, Providers and policy developers to understand the risks and impact of current practice nationally.

Thrombosis UK has used the findings from the FOI to encourage reinstatement of national VTE risk assessment data collection and publication of VTE data across HES and Outcomes Indicator Frameworks. Not only has a paper been submitted to the 'Health Service Journal,' but the charity has also promoted our findings in media coverage, presentations and discussion across the sector. NHS Patient Safety are strongly supportive and working with us to advocate for the reinstatement of mandated VTE Risk Assessment and reporting.

National Thrombosis Week

During 2023 the Charity continued to focus on increasing awareness through presence and involvement in fundraising events. The first, National Thrombosis Week fundraiser was launched and invited everyone, regardless of health, mobility or age. The event, '5K your way in May' shared activities from multiple supporters from across the UK on social media and raised over £2,800. The activity was a catalyst for further support and resulted in the first year in which fundraising topped £100,000 in the first six months of the year. The accessible and inclusive nature of the charity's fundraising efforts has paid dividends not only in sums raised, but also in improving sustainable engagement with supporters thanks to a stronger sense of community.

A number of fundraisers utilised the Crowdfunder website to increase their 'in memory' appeals. Not only was this successful, raising more than £8,000, but increased awareness of thrombosis and Thrombosis UK amongst the general public and audiences who would not usually have had contact with the charity.

VTE Awards in Parliament

Thrombosis UK was delighted to launch the **VTE Awards**, hosted by Lyn Brown MP and held in Houses of Parliament in November 2023. Communications with MPs and via Local Health Trusts raised awareness and provided news of the short-listed candidates. The Charity also shared insight on effective VTE pathways that were making a difference to patient safety, care and outcomes. Awards were made in six categories covering VTE prevention, diagnosis, management, patient experience, patient resources and Thrombosis UK Life-time Achievement Awards. Dr Adrian Fowles (NHS Patient Safety) attended and shared an update on NHS work prioritising VTE prevention, including the reinstatement of VTE Risk Assessment reporting for all English hospitals.



Education

The 2021 NHS Getting It Right First Time (GIRFT) Thrombosis Report highlighted a significant lack of patient information about VTE in hospitals. The report recommended improved provision and access for patients to information about VTE.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

In response to GIRFT recommendations, and in recognition of the severe financial pressures the NHS is experiencing, Thrombosis UK developed and funded a patient information VTE prevention card and offered these free of charge to UK hospitals. Distribution continued during 2023 via staff in hospital and community medical settings, taking the number of patient printed resources being distributed to over one million in the past 18 months. However, the Charity recognised that:

- Sustainability of cost was challenging.
- Each resource only addressed one element of VTE.
- Access heavily relied upon distribution by healthcare professionals, resulting in variability across regions and even within hospitals.

A new approach was needed that could address the shortcomings of the existing resources programme.

So, in 2023, Thrombosis began work on a patient information app – named **Let's Talk Clots**. Clinical expertise was built in from the start, thanks to a close collaboration with Sarah Havord, VTE prevention lead at Oxford NHS University Hospitals Trust.

The app would:

- Provide medically approved, patient reviewed information.
- Resources would include information across the VTE pathway, from 'What is a VTE?' to 'Signs and symptoms.'
- The app would offer a one-stop shop for support through diagnosis, treatment and recovery.
- This would be supported by a 'chat' function and resources on specific health related areas of VTE including pregnancy, cancer and being admitted into hospital.
- Include answers to frequently asked questions throughout each section.

Funding towards the app was secured through the charity's successful application for an International Society for Thrombosis and Haemostasis (ISTH) Legacy Grant. Thirty healthcare professionals and 12 patient representatives helped to develop, draft and review content. This amazing team full of passion and enthusiasm for the project, ensured the app was completed within five months, being officially launched in the Houses of Parliament on 23rd November 2023.

By 31st January 2024, just two months post-launch, the app had been downloaded 1,381 times with a 92% access and used rate, by individuals from 42 countries¹.



¹ Argentina, Australia, Algeria, Bangladesh, Bulgaria, Belgium, Canada, Chile, Cyprus, Denmark, Egypt, France, Greece, Hungary, India, Iraq, Italy, Jersey, Jordan, Kuwait, Isle of Man, Malaysia, Namibia, Norway, Netherlands, New Zealand, Pakistan, Palestine, Portugal, Romania, Saudi Arabia, Singapore, Paraguay, Philippines, Somalia, S Africa, Spain, Sudan, Thailand, Switzerland, UEA, USA.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

National Thrombosis Week and Let's Talk Clots virtual conferences

In 2023, Thrombosis UK hosted two accredited online conferences for healthcare and allied professionals as part of the National Thrombosis Week and World Thrombosis Day celebrations.

The Thrombosis UK conferences have become synonymous with excellence, and each conference has seen registration numbers increase year on year:

- 2,556 NTW'23 and
- 2,600 for LTC'23.

We have been fortunate to welcome an international faculty and in October 2023 provided three very special 'LTC Master Classes' with sessions lead by:

- Prof Fionnuala Ni Ainu, with panel members: Dr Marc Blondon, Dr Leslie Skeith, Dr Robert-Ebadi, Dr Barry Kevane & Prof Mark Rogers
- Dr Jean Connors, and
- Prof Jeff Weitz.

Alongside the Master Classes, sessions welcomed collaboration with professional bodies for primary care (PCCS), VTE nursing (VTE-SN) and pharmacists (UKCPA-HAT).

New for both 2023 conferences, was:

- The introduction of an 'Poster Hall' from which four submissions were selected for a dedicated 'Oral Presentation' session within the main agenda.
- A roundtable group meeting facility providing opportunity for face-to-face discussion and peer support.

Feedback was overwhelmingly positive, praising:

- Agenda.
- Range of topics.
- Ease of navigation around the platform and introduction of an app.
- 24/7 access for an extended period.

In support of



Advancing understanding
Informing practice

10-13 OCTOBER 2023

Thrombosis UK
MEMBER OF REGAIN



Patient information

The patient information app, 'Let's Talk Clots', has provided a fresh platform to share information and engage awareness.

New resources, largely developed from the REGAIN project and app, including a 'Glossary of Terms,' have all been well received, and work was initiated in January 2024 to update and extend the current library of Thrombosis UK patient information resources.

All Thrombosis UK resources are available free of charge to individuals online. However emphasis has been placed on dissemination of the app, as this provides free, instant, ease of access to the greatest breadth of information for all users. Furthermore, it is easily updated and very cost-effective. Thrombosis UK has advertised across social media platforms via HCP providers. Example text and QR codes have been made available to all medical settings who have ordered free posters and postcards about the app, so that they can include information on admission and discharge hospital letters and follow-up communications.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

In the first two months of distribution, 40,000 app awareness postcards and posters were distributed to medical settings.



Patient meetings

In collaboration with medical research groups, the charity hosted three **patient and public involvement (PPI) meetings** with UK Thrombosis Research Network (UK-TrEN), HaemSTAR, and Oxford University Hospitals NHS Foundation Trust. Interest in becoming involved in this way has been high, and the sessions proved to be a very effective way to share information about proposed research studies as well as seek involvement, ideas and comment from patient representatives.

Interest to attend online information and support meetings continues, and a programme of regular sessions was developed to cover popular topics, frequently asked questions and peer to peer support. These included 'Coping with...' webinars for individuals following a diagnosis of VTE. Led by Professor Paul Bennett, Clinical Psychologist with Thrombosis UK, the sessions addressed many of the issues experienced due to the psychological impact of thrombosis.

REGAIN project

Thrombosis UK's **REGAIN project**, was established to provide free, on-line access to clinical psychological support for individuals diagnosed with Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), but who were unable to access local psychological support.

The REGAIN programme sought to raise awareness of the impact of VITT through research, education, and resources in order to:

1. Improve every patient's recovery.
2. Inform future planning and development of VTE care pathways.
3. Improve every patient's experience of thrombosis.

The programme has been well received by users and has produced valuable support resources for individuals affected by the impact of VITT or venous thromboembolism (VTE).

In December 2023, two papers were published in the BMJ,

- *'Qualitative study of the consequences of vaccine-induced immune thrombocytopenia and thrombosis: the experiences of family members,'*
- *'Living with vaccine-induced immune thrombocytopenia and thrombosis: a qualitative study.'*

In 2023, as VITT numbers naturally decreased, the service began to accept referrals from individuals who had a diagnosis of VTE and had experienced psychological impact from this but were unable to access local psychological clinical support. Professor Bennett reached out to UK-wide VTE services and shared information on the resources available and the pathways for referral into the service.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

As a result, during 2023, Professor Bennett was able to provide places for 60 individuals to the REGAIN 1-1 clinical psychology support, 48 of whom had a diagnosis of VTE and 12 with VITT. Twelve small group information and support meetings were held for individuals experiencing excessive anxiety and worry, following a VTE or VITT diagnosis.

In January 2024, the Board of Trustees reviewed a business plan to extend REGAIN through:

- Inclusion of patients significantly struggling with the psychological impact of a VTE and without access to local clinical support services.
- Develop the provision of online small group meetings and recorded resources to assist those mildly affected.
- Develop an accredited online training course for healthcare and allied professionals aimed at supporting improved communications between patients and healthcare providers.
- Provide local educational support and sessions to UK wide HCP providers.
- Extend patient information resources for this area.

The Board agreed to extend Professor Bennett's contract for a further two years, until 31st January 2026 for this work to be developed.

Missed diagnosis of VTE

The issue of missed diagnosis of VTE is a frequent theme from individuals and families contacting Thrombosis UK, and too often, highlights the tragic loss of a loved one that could potentially have been prevented.

In 2023, NHS Resolution published '*Venous Thromboembolism*' which documented 687 closed claims relating to Venous Thromboembolism (VTE) injuries. Of these, 411 claims were settled with damages paid, costing the NHS over £23 million and highlighting VTE as a significant cause of mortality, long-term disability and long-lasting ill-health problems – many instances of which are avoidable. NHS Resolution provided a digital resource detailing how clinicians should take preventative action to improve outcomes for patients at risk of VTE.

During 2023, Leads from Thrombosis UK supported educational events in collaboration with NHS Resolution, to promote learning and practice from their work [<https://resolution.nhs.uk/wp-content/uploads/2023/03/Did-you-know-VTE-final-amended.pdf>].

Did you know?

Venous thromboembolism (VTE) is an umbrella term for deep vein thrombosis and pulmonary embolism.

A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

VTE is a significant cause of mortality; long term disability and long-lasting ill health problems – many of which are avoidable. 1 in 20 people will have a VTE at some time in their life and the risk increases with age.

It is estimated that as many as half of all cases of VTE are associated with hospitalisation for medical illness or surgery. Pregnancy is also a VTE risk factor.^{1,2}

The risk of developing VTE is highest after major surgery, a major injury or periods of immobility following hospitalisation. Swelling, redness, and pain in a limb are some of the symptoms of DVT. A PE can cause sudden chest pain and shortness of breath.

A missed or delayed DVT diagnosis may result in fatal PE. Diagnostic algorithms and risk assessments are in place to help clinicians with the diagnosis.

In 2022, NHS Resolution published thematic reviews looking at high value and fatality related claims in emergency departments, RDY and general practice related claims. VTE featured amongst the most common causes of mortality related to a missed diagnosis in ED, and established that VTE is a theme in general practice claims, emphasising the range of clinical settings.

Figure 3: Number of VTE claims by top 10 causes

Top 10 Causes	Number of Claims
Publications reviews	247
Healthcare claims	104
Emergency department	84
Admission to emergency department	64
Failure to prevent harm	64
Healthcare associated infection	64
Failure to follow up emergency	64
Preventable medication	64
Other	64
Other	64

Continuing our work in raising awareness of this issue, in September 2023, Thrombosis UK hosted a **Parliamentary Round Table Meeting** in Portcullis House, initiated by Tim Edwards, whose mother died as a result of a missed diagnosis of pulmonary embolism (PE), and Helen Hayes MP.

The meeting also heard from Debbie Budden, whose partner, Gary, died following a missed diagnosis of VTE, as well as and UK Health Leads, Royal Colleges and representatives from public bodies. A report from this meeting is to be published in 2024.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

Research into improving early diagnosis of VTE

Following discussions between Thrombosis UK, VTE Exemplar Network leads, NHS GIRFT and NHS Patient Safety, Thrombosis UK was successful in securing educational research grants totalling £255,020 to initiate a study seeking to improve understanding of the common barriers and causes causing delay in early diagnosis of VTE.

Led by Thrombosis UK with endorsement from NHS GIRFT, 'Detect VTE' was launched in December 2023, with the charity reaching out to UK wide primary care practices to secure interest for Stage One – VTE audit. This focused on tracking patient journeys in the eight weeks prior to them receiving a diagnosis of VTE diagnosis within the past 12 months.

Interest was much greater than we had anticipated, and within four weeks 54 UK primary care practices had registered an interest. Each practice was offered an audit for VTE, and receive an individual report and, if requested, follow-up education and discussion to support implementation of learning from the practice-specific audit report.

Following individual meetings with each practice, audit began in January 2024 and are expected to complete by June 2024 having reviewed in excess of 370,000 records. Once completed analysis of the national data will commence. No patient identifiable data was collected or taken from the practice's database at any point.

It is intended, that this work, in collaboration with NHS GIRFT, NHS Patient Safety and related Royal Colleges, will enable to learning to inform and benefit:

- Early medical training.
- Continued professional training.
- Awareness.
- A clinical solutions tool to support early clinical recognition of potential indicators of VTE, will be developed and offered free of charge to UK wide medical practices.

Research Publications

As a result of work undertaken in the REGAIN project, Professor Bennett was successful in securing publication of two papers in the British Medical Journal (BMJ).

The first paper looked at patient experience of Vaccine-induced Immune Thrombosis and Thrombocytopenia (VITT). This has reached the 98th percentile of research interest on altimetric digital services, showing 4,500 downloads at the time of writing this report.

The second paper, looking at family experience, reached the 95th percentile of digital research interest and had over 3,000 downloads as at time of writing this report.

Professor Bennett's work with the REGAIN project and specifically related to VITT, resulted in him being nominated by multiple VITT support groups to the COVID-19 inquiry to be called as an Expert Witness and speak of the psychological consequences of VITT.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

Fundraising

Fundraising supporters took part in events across the UK, from private and individual challenges to virtual races, cycle rides, runs, walking challenges and tournaments.

We welcomed a return of our repeat fundraisers with Will Jebson continuing his, 'Fishing for Thrombosis' event and extending this to hold two events per year. Brenda Christopher led a team of repeat fundraisers in the 'Shoreham 10K'. Our regular event fundraiser Peter Tinston completed the Royal Parks Half for a second year in memory of his late wife and long-time Thrombosis UK supporter, Dawne.

Thrombosis UK is immensely grateful to all who fundraise and donate to the charity for our work to continue. Tragically, support often comes after personal suffering or loss, and Thrombosis UK would like to thank supporters and reiterate that their fundraising helps to make a significant difference to understanding, raising awareness of and supporting individuals affected by venous thromboembolism. Due to the efforts of our fundraisers, we can be there for anyone at risk of, or diagnosed with a blood clot, or who has lost a loved one due to VTE,

Authors Dawne Archer and Ken Gregory continued to donate funds raised from the sales of each of their books to Thrombosis UK. With their very active social media accounts, again, their help not only raises funds but successfully increases awareness of thrombosis and the charity.

The charity is also grateful to supporters who secured match-funding from employees, along with corporate fundraisers such as Lincolnshire Housing.

When we review support and success in fundraising, we also wish to thank and pay tribute to our longest serving fundraisers: Minion Green, Rachel Pitson, John Humphreys and Brian Houten, who individually, continue to organise events, fundraise or make annual donations to Thrombosis UK. Thank you.

ACHIEVEMENTS AND PERFORMANCES

Significant activities and achievements

- The library of 249 Thrombosis UK films received over 100,233 views taking total views to over one million!
- 750,000 free, medically approved, printed patient information resources were distributed to UK medical settings.
- We welcomed over 5,000 attendees to our 2023 healthcare conferences from across the globe.
- Secured 32 Continued Professional Development (CPD) points for 2023 Thrombosis UK conferences.
- Launched Let's Talk Clots app providing information about blood clots across the VTE pathway.
- Within two months following launch, resources on the Let's Talk Clots app received
 - 3,601 views
 - 940 document downloads
 - 215 film views
- Hosted three 'Patient and Public Involvement' meetings involving 54 patient representatives.
- REGAIN clinical psychology programme provided 366 one-to-one clinical psychology sessions for 60 individuals.
- Collaborated with nine professional bodies and NHS entities to increase VTE awareness, learning and educational opportunities for all healthcare professionals.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31ST JANUARY 2024

- Launched the national 'VTE Awards,' sharing effective practice in VTE prevention and management.
- Thrombosis UK featured on Sky Morning News, talking about VTE risk assessment and missed diagnosis.
- A 32% increase from 2022 in the number of fundraisers supporting Thrombosis UK.
- In 2023 we saw a 31% increase in trackable fundraising revenue on the previous year.
- Secured grants totalling just over £255,000 to support the Detect VTE programme of work.

Government & Policy

In July 2023, changes in requirements for All Party Parliamentary Groups (APPG) were published and needed to be implemented by 31st March 2024 or the individual's annual general meeting (AGM), whichever was earliest.

Thrombosis UK has been the secretariat for The All Party Parliamentary Group for Thrombosis (APPGT) since 2019, and hence, when the APPGT AGM was held in January 2024, the changes were discussed. The group agreed, due to significant increase in required supporter numbers and restrictions on the number of APPGs MPs and Peers could be Officer to, it was decided that the APPGT would need to disband, unable to meet the new requirements. The Parliamentary Office for APPGs was notified by Lyn Brown MP, Chair of the APPGT in January 2024, that the group had disbanded.

Thrombosis UK maintained regular communication with NHS England during 2023, in particular NHS Patient Safety and NHS GIRFT Leads, to continue to focus on VTE and work towards:

- Reinstatement of VTE Risk Assessment reporting for all NHS England hospitals.
- Work on the 'Detect VTE' initiative.

Both NHS GIRFT and NHS Patient Safety endorsed plans for Detect VTE and regular update meetings were planned to review approach, progress and ensure maximum benefit could be gained from this extensive project.

FINANCIAL REVIEW

During the year ended 31 January 2024 the charity made a surplus of £255,442 (2023: deficit of £12,264). Total incoming resources saw an increase of 151% and expenditure increased by almost 17% in the year. The material increase in incoming resources was as a result of successfully receiving restricted grant monies (see Note 3 to the financial statements). The virtual events and activities incurred a generally lower expenditure requirement. However, the majority of the increase in expenditure was as a result of the charity's appointment of a Senior Clinical/Counselling Psychologist to lead the REGAIN psychological support programme. The economic and political uncertainty continues to affect the ability of the charity to meaningfully forecast corporate and individual funding commitments and, as with last year, although the charity budgeted to meet its planned charitable activities through funds raised in the year it was prepared to have to utilise a proportion of its general unrestricted reserves if necessary.

The net assets of the charity have been retained and have increased from £411,778 in 2023 to £667,220 and this fits with the reserves policy of the charity.

The Statement of Financial Activities is presented on page 19.

PLANS FOR FUTURE PERIODS

The extended adoption of virtual events, in particular educational webinars, conferences, and meetings, has continued to enable the charity's work to grow and extend across:

- Reach.
- Global collaborations.
- Ease of access for patients, the general public and healthcare professionals to access information, support, and training.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

The online platform has not only proven to be more cost-effective, but also received extremely positive feedback from faculty, attendees, and sponsors. While the recording of sessions ensured a lasting legacy to access high quality education.

The inaugural meeting for the newly formed Thrombosis UK 'Professional Advisory Committee' (PAC), was held in 2024. Formed with representatives from across the UK from health care and patient supporters, this committee will:

- To represent VTE stakeholders across the UK.
- Identify and inform Thrombosis UK on relevant and key areas of VTE which should be included in the charity's strategy for delivering its 'Awareness, Research and Care' goals.
- Provide input and guidance on update or development of resources, conference agendas and advocacy activities across the UK NHS systems.
- Be a first line referee for grant proposals or applications.
- Represent Thrombosis UK as an ambassador.

In reviewing plans for 2024/25, while Thrombosis UK is mindful of the benefits of personal interaction the charity is keen to enable increased access and the virtual platform and recording of webinars is currently enabling both greater access and a learning legacy. However, we are mindful that continued monitoring is important and so the charity, along with review from the PAC, will continue to carefully consider feedback, access and opportunity to ensure we are delivering in the most effective and efficient style suitable and welcomed by UK healthcare practitioners.

REFERENCE AND ADMINISTRATION DETAILS

A Board of ten Trustees, who are also Directors of the company, govern Thrombosis UK. The Trustees have the power to appoint and remove any member to act as Secretary to the charity and all - vote on the appointment of the Chairman, Treasurer, and other Honorary Officers. The charity seeks to ensure trustees are appointed to fulfil the changing and on-going needs of the charity's activities and outcomes. New trustees are appointed with the unanimous approval of existing trustees.

All Trustees give freely of their time and expertise and receive no remuneration for their work as trustees. The current list of trustees, who acted throughout the period of review, is given on page one.

Trustees unanimously agreed to adopt a rotational model for the role of Medical Director of Thrombosis UK, with each appointee in post for two-three years. In April 2016 Professor Simon Noble accepted an invitation to this role taking up the post in June 2016, with the objective of allowing for fresh ideas to percolate through the organisation. In November 2020 the Trustees agreed to extend retaining current directors for an extended 12 months while Governance work continued with the objective to write Trustee roles and job descriptions and develop a new Constitution. This work continues, and agreement was again in 2023 for this to be extended in order to implement a robust succession plan for Trustees so that skills, knowledge and experience are not lost, but instead, built on to secure the safe governance of Thrombosis UK.

Trustees' meetings are held a minimum of twice per year. Email correspondence is used to keep Trustees updated in between meetings and the CEO meets with Thrombosis UK's Medical Leads and /or Chair of Trustees between four-six times per year to discuss projects and agreed strategic and directional development.

TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees (who are also directors of Thrombosis UK for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year.

THROMBOSIS UK

Registered Charity No: 1090540

Company No.: 4354472

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP).
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting Standards have been followed.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In accordance with company law, the Trustees certify that:

- so far as we are aware, there is no relevant audit information of which the company's auditors are unaware; and
- as Trustees we have taken all the steps that we ought to have taken in order to make ourselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

AUDITORS

The Auditors, Messrs Couch Bright King & Co., have expressed their willingness to continue in office and a resolution proposing their re-appointment will be put to the Trustees at the forthcoming Annual General Meeting.

SMALL COMPANY EXEMPTION

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

The Trustees who were in office on the date of approval of the financial statements have confirmed, as far as they are aware, that there is no relevant audit information of which the auditors are unaware. Each of the Trustees have confirmed that they have taken all the steps that they ought to have taken as Trustees in order to make themselves aware of any relevant audit information and to establish that it has been communicated to the auditors.

RESERVES POLICY

In the course of the development of the charity we will take account of the need to have reserves, and a policy, to honour future funding commitments that we make. We will also ensure that funds are sufficient to cover one year's charitable activity plus sufficient funds to cover all operating costs of the charity.

RISK ASSESSMENT

We consider the systems we have in place for the day-to-day operation of Thrombosis UK to be appropriate to our current size of operation, but we are aware that as we grow, we will need to develop and implement procedures and reporting regimes to mitigate the risks associated with running a charitable company.

THROMBOSIS UK

**Registered Charity No: 1090540
Company No.: 4354472**

TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2024

PUBLIC BENEFIT

The Trustees confirm, to the best of their knowledge and belief, that they have complied with Section 4 of The Charities Act 2011 in respect of having due regard to Public Benefit Guidance published by the Charity Commission.

Approved by the Trustees on: 16th October 2024



Prof Ian M Franklin
Trustee

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540**

Opinion

We have audited the financial statements of Thrombosis UK for the year ended 31st January 2024 which comprise the primary statements such as the Statement of Financial Activities including Income and Expenditure Account, the Balance Sheet, the Statement of Cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Generally Accepted Accounting Practice including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31st January 2024 and of its incoming resources and application of resources; including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to smaller entities;
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540**

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the Trustees' Responsibilities Statement set out on page 13, the Trustees (who are also the directors of the charitable company for the purposes of the company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

We have;

- Obtained an understanding of the legal and regulatory framework applicable to the entity and how the entity is complying with that framework;
- Obtained an understanding of the entity's policies and procedures on compliance with laws and regulations, including documentation of any instances of non-compliance;
- Identified the laws and regulations that have significance in the context of the entity;
- Obtained an understanding of the entity's risk assessment process, including the risk of fraud;
- Assessed and evaluated the susceptibility of the entity's financial statements to material misstatement, through error and fraud;

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THROMBOSIS UK
Registered Charity No: 1090540**


- Implemented procedures to enable the identification and testing of unusual or unexpected journal entries;
- Evaluated the assumptions and judgements used by management within significant accounting estimates and assessed if these indicate evidence of management bias;
- Tested significant transactions, in particular the evaluation of the business rationale for any which appear unusual or outside the company's normal course of business;
- Reviewed the financial statements and tested the disclosures against supporting documentation;
- Communicated relevant matters (including those above) to all members of the audit team to ensure they understood the risks specific to the entity and the audit procedures planned to mitigate these.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members as a body, for our audit work, for this report, or for the opinions we have formed.



Ms Tarwa Mohammed BA FCA (Senior Statutory Auditor)
For and on behalf of
Couch Bright King & Co
Chartered Accountants &
Statutory Auditors

2 Tolherst Court
Turkey Mill Business Park
Ashford Road, Maidstone
Kent ME14 5SF

15th October 2024

THROMBOSIS UK

Registered Charity No: 10905401

Company No: 4354472

**STATEMENT OF FINANCIAL ACTIVITIES
(Including Income and Expenditure Account)
FOR THE YEAR ENDED 31 JANUARY 2024**

	Notes	Unrestricted			Year to 31.1.24	Year to 31.1.23
		General Funds	Designated Funds	Restricted Funds	Total Funds	Total Funds
		£	£	£	£	£
Income:						
Donations, legacies and gifts	3	177,021	-	301,447	478,468	171,066
<i>Income from Charitable activities:</i>	4					
Educational meetings		-	-	-	-	2,000
Events - Sponsorship		23,750	-	-	23,750	22,680
<i>Income from other trading activities:</i>	5					
Online shop		-	-	-	-	1,964
Awareness Literature		630	-	-	630	224
Other Income		703	-	-	703	-
<i>Investment Income</i>						
Bank Interest		3,367	-	-	3,367	3,968
Total income		205,471	-	301,447	506,918	201,902
Expenditure						
Costs of raising funds	6	4,702	-	-	4,702	4,212
Costs of charitable activities	7	202,594	-	44,180	246,774	209,954
Total Expenditure		207,296	-	44,180	251,476	214,166
Net income and Net movements in funds		(1,825)	-	257,267	255,442	(12,264)
Transfers		-	-	-	-	-
Net movements in funds		(1,825)	-	257,267	255,442	(12,264)
Reconciliation of funds						
Total funds At 1 February 2023		384,132	740	26,906	411,778	424,042
Total Funds At 31 January 2024	14	382,307	740	284,173	667,220	411,778

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

THROMBOSIS UK

**Registered Charity No: 1090540
Company No: 4354472**

**BALANCE SHEET
AS AT 31 JANUARY 2024**

	Notes	2024 £	2023 £
Fixed Assets			
Tangible fixed assets	10	-	-
Current Assets			
Debtors	12	22,027	27,939
Cash at bank and in hand		667,574	402,951
		<u>689,601</u>	<u>430,890</u>
Creditors (amounts falling due within one year)	13	22,381	19,112
Net Current Assets		<u>667,220</u>	<u>411,778</u>
Net Assets		<u>667,220</u>	<u>411,778</u>
Represented by:			
Restricted funds	14	284,173	26,906
Designated Funds	14	740	740
Unrestricted funds			
General funds	14	382,307	384,132
Total unrestricted funds		<u>667,220</u>	<u>411,778</u>
Total funds		<u>667,220</u>	<u>411,778</u>

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees on 14th October 2024

Signed on their behalf by


Simon Hart
Trustee


Prof Ian M Franklin
Trustee

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 JANUARY 2024**

	Note	2024 £	2023 £
Cash flows from operating activities:			
Net movements in funds for the year		255,442	(12,264)
		<hr/>	<hr/>
Movements in working capital		255,442	(12,264)
Dividends and interest from investments		(3,367)	(3,968)
Decrease/(Increase) in Debtors		5,912	(15,732)
(Decrease)/Increase in Creditors		3,269	(3,337)
		<hr/>	<hr/>
Net cash generated by operating activities		261,256	(35,301)
		<hr/>	<hr/>
Cash flows from investing activities:			
Dividends and interest from investments		3,367	3,968
Proceeds from sale of investments		-	-
Purchase of investments		-	-
		<hr/>	<hr/>
Cash used in investing activities		3,367	3,968
		<hr/>	<hr/>
Increase in cash and cash equivalents		264,623	(31,333)
Cash and cash equivalents at beginning of the year		402,951	434,284
		<hr/>	<hr/>
Cash and cash equivalents at the end of the year	11	667,574	402,951
		<hr/> <hr/>	<hr/> <hr/>

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2024

1) Statutory Information

a) Company Status

The charity is a company limited by guarantee, incorporated in England and Wales. The registered office is 2 Tolherst Court, Turkey Mill Business Park, Ashford Road, Maidstone, Kent ME14 5SF. The principal office address is PO. Box 58, Llanwrda, Carmarthenshire, SA19 0AD.

The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

b) Charitable Status

Thrombosis UK is a registered charity, registration number 1090540 and in consequence is exempt from taxation on income arising from and expended on its charitable activities.

2) Accounting Policies

The principal accounting policies, all of which have been applied consistently throughout the year, are set out below:

a) Basis of Preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

Thrombosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

b) Functional and presentation currency

The company's functional and presentation currency is GBP.

c) Going Concern

The Trustees continue to adopt the going concern basis in preparing the financial statements and confirm there are no material uncertainties about the charity's ability to continue as a going concern.

d) Fixed Assets and Depreciation

Depreciation is charged on a straight-line basis, in order to write off the assets over their useful economic lives as follows:

Computer and Other Equipment over 3 years

Assets acquired under a value of £1,500 are charged to the Statement of Financial Activities in the year of acquisition.

e) Income and Expenditure recognition

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received, and the amount can be measured reliably. Income is deferred to match the period of the terms of the grant documentation or terms of agreement where applicable.

The Charity, in common with many others of a similar size and organisation, derives a substantial proportion of its income from voluntary donations. Such donations are recognised and entered into the accounting records when they are received. Other income, such as bank interest, is accounted for on an accruals basis. All expenditure is accounted for on accruals basis.

f) Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2024**

g) Unrestricted Fund

Unrestricted funds are donations, gifts and other incoming resources receivable or generated for the objects of the charity without further specified purpose and are available as general funds or for purposes as designated and agreed by all the Trustees.

h) Designated Fund

Designated funds (where applicable) are unrestricted funds earmarked by the Trustees for particular purposes.

i) Restricted Fund

Restricted funds are donations, gifts and other incoming resources receivable or are generated for the objects of the charity with a specified purpose. They can only be used in accordance with the donor's wish or by the terms of a public appeal.

	<u>2024</u>	<u>2023</u>
	£	£
3) Donations and gifts		
<u>Restricted</u>		
Research	1,000	945
REGAIN Programme	753	3,193
Education Grant	16,000	14,500
Detect VTE Audit Study	255,020	-
ISTH Grant 2022	28,673	-
<u>Unrestricted</u>		
Donations	157,721	137,041
Gift Aid	19,301	13,537
Education Grant	-	1,850
	478,468	171,066
	478,468	171,066

The number of general donations we have received during the year has seen a small increase compared to prior year. Thrombosis UK is immensely grateful to all of those who have organised a fundraising event for the charity.

	<u>2024</u>	<u>2023</u>
	£	£
4) Income from charitable activities		
Educational Meetings	-	2,000
Events - Sponsorship	23,750	22,680
	23,750	24,680
	23,750	24,680
5) Income from other trading activities		
Online shop – ebay sales	703	1,964
Awareness Literature	630	224
	1,333	2,188
	1,333	2,188
6) Costs of raising funds		
Donations	2,956	4,212
Events	1,746	-
	4,702	4,212
	4,702	4,212

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2024**

7) Analysis of costs of charitable activities	<u>Restricted</u>	<u>Unrestricted</u>	<u>2024</u>	<u>2023</u>
	£	£	£	£
Research Grant	6,097	-	6,097	-
Awareness Resources	-	26,806	26,806	12,836
Awareness Literature	16,000	24,492	40,492	17,309
Thrombosis Education		9,454	9,454	15,237
Website & App Costs	14,605	1,790	16,395	22,080
Support Costs (Note 8)	7,478	128,328	135,806	130,366
Governance Costs (Note 8)	-	11,724	11,724	12,126
Total	<u>44,180</u>	<u>202,594</u>	<u>246,774</u>	<u>209,954</u>

8) Analysis of Support and Governance costs

Thrombosis UK initially identifies its support costs which relate to the governance function and then the remaining support costs are apportioned as follows;

	General Support	Governance Function	Total 2024	Basis of apportionment
	£	£	£	
Trustee and other business meetings	-	309	309	Invoiced events
Salaries, wages and related costs	124,538	-	124,538	Allocated on time
General Office	11,268	-	11,268	Invoiced events
Audit fees	-	6,600	6,600	Governance
Legal and other professional fees	-	4,815	4,815	Governance
	<u>135,806</u>	<u>11,724</u>	<u>147,530</u>	
	General Support	Governance Function	Total 2023	Basis of apportionment
	£	£	£	
Trustee and other business meetings	554	-	554	Invoiced events
Salaries, wages and related costs	118,310	-	118,310	Allocated on time
General Office	11,502	-	11,502	Invoiced events
Audit fees	-	6,300	6,300	Governance
Legal and other professional fees	-	5,826	5,826	Governance
	<u>130,366</u>	<u>12,126</u>	<u>142,492</u>	

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2024**

		<u>2024</u>	<u>2023</u>
		£	£
9)	Staff costs		
	Salaries	113,260	107,153
	Employers National Insurance	5,395	5,261
	Pensions	5,883	5,272
		<u>124,538</u>	<u>117,686</u>
		<u>124,538</u>	<u>117,686</u>
	 The average number employed during the year was	<u>4</u>	<u>4</u>
	 There are no employees with emoluments above £60,000. The Key Management Personnel of the charity comprise the Trustees and the Chief Executive Officer. The Trustees have not received any remuneration for their work as Trustees. The total employee benefits of the Key Management Personnel were £48,931 (2023: £41,540).		
10)	Fixed Assets		
		<u>Computer</u>	
		<u>Equipment</u>	<u>Total</u>
	<u>Cost</u>	£	£
	At 1 st February 2023	4,697	4,697
	Additions	-	-
		<u>4,697</u>	<u>4,697</u>
		<u>4,697</u>	<u>4,697</u>
	 <u>Depreciation</u>		
	At 1 st February 2023	4,697	4,697
	Charge for year	-	-
		<u>4,697</u>	<u>4,697</u>
		<u>4,697</u>	<u>4,697</u>
	Net Book Value 31 st January 2024	<u>-</u>	<u>-</u>
		<u>-</u>	<u>-</u>
	Net Book Value 31 st January 2023	<u>-</u>	<u>-</u>
		<u>-</u>	<u>-</u>
		<u>2024</u>	<u>2023</u>
		£	£
11)	Cash and cash equivalents		
	Cash at Bank	667,574	402,951
		<u>667,574</u>	<u>402,951</u>
		<u>667,574</u>	<u>402,951</u>
12)	Debtors		
	Gift Aid	5,439	4,329
	Prepayments & Accrued Income	16,588	23,610
		<u>22,027</u>	<u>27,939</u>
		<u>22,027</u>	<u>27,939</u>
13)	Creditors: Amounts falling due within one year		
	Other taxes	3,172	1,653
	Grants Payable	7,900	2,900
	Other creditor & Accruals	11,309	8,559
	Deferred Grants	-	6,000
		<u>22,381</u>	<u>19,112</u>
		<u>22,381</u>	<u>19,112</u>

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2024**

14) Movement in Funds

	At 1 st February 2023 £	Incoming Resources £	Outgoing Resources £	Transfers £	At 31 st January 2024 £
Restricted funds:					
Research	5,459	1,000	-	-	6,459
Education & Awareness Grant	-	16,000	16,000	-	-
REGAIN Programme	13,304	753	1,097	-	12,960
VTE Grand Appeal	8,143	-	5,000	-	3,143
ISTH	-	28,674	14,605	-	14,069
Detect VTE Audit Study	-	255,020	7,478	-	247,542
Total restricted funds	<u>26,906</u>	<u>301,447</u>	<u>44,180</u>	<u>-</u>	<u>284,173</u>
Unrestricted funds:					
Designated Funds					
REGAIN Programme	740	-	-	-	740
General Funds	384,132	205,471	207,296	-	382,307
Total unrestricted funds	<u>384,872</u>	<u>205,471</u>	<u>207,296</u>	<u>-</u>	<u>383,047</u>

Purpose of Restricted Funds

Research – There was a donation of £1,000 (2023: £945) received towards the Thrombosis UK Research Fund in the year.

REGAIN Programme - Thrombosis UK launched innovative ‘REGAIN’ clinical psychology research service programme for people recovering from VITT. In 2021, the charity was successful in securing a grant donation towards the development of a comprehensive research and support programme to combat the psychological impact of VTE (including COVID -19) and VTT thrombosis patients. During this year, this programme received £753.

Education & Awareness Grant – Thrombosis UK received total grants of £16,000 towards the printing and distribution costs of patient information VTE prevention ‘Z’ cards.

Purpose of Unrestricted Funds

General funds balance includes:

(i) Designated Funds – REGAIN Programme

Thrombosis UK launched an innovative ‘REGAIN’ clinical psychology research service programme for people recovering from VITT. The Trustees designated £nil (2023: £ nil) grant donation received in the year towards this programme.

(ii) General - Thrombosis UK is committed to raising awareness and advancing thrombosis research in the UK. The Trustees have decided that as much as possible of the money donated by the general public will be used towards these objectives.

Events - Sponsorship fees received to enable the charity to widen the Public and Health Professionals’ awareness of thrombosis and the related issues. Sponsorship fees of £23,750 were received in the year to support the ‘Let’s Talk Clots’ Virtual Conference held in October 2023, the National Thrombosis Week in May 2023 and World Thrombosis Day Virtual conferences held during the year.

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2024

Transfers between funds

There were no transfers between funds in the year.

15) Capital Commitments

There are no outstanding commitments as at 31 January 2024.

16) Contingent Liabilities

There are no contingent liabilities to report as at 31 January 2024.

17) Post Balance Sheet Events

There are no adjusting or non-adjusting events to report as at 31 January 2024.

18) Trustee Remuneration

The Trustees have not received any remuneration for their work as Trustees. Expenses totalling £309 (2023: Nil) have been reimbursed to two Trustees.

19) Related Party Transactions

The ISTH 2022 Annual Congress Legacy Fund, under the governance of the International Society on Thrombosis and Haemostasis (ISTH), allows for the distribution of funds based on recommendations from the Chair of the Annual Congress. During 2022, the Chair was Dr Beverley Hunt, who serves as a trustee for Thrombosis UK (TUK). ISTH granted, TUK approximately £28.5k (equivalent to \$37.5k) to support the development of a VTE (Venous Thromboembolism) Patient Information App, aimed at enhancing patient access to vital information related to VTE.

There were no other Related Party Transactions in the year.

20) Taxation Status

The company being a registered charity (No.1090540) is not liable to Income and Corporation Taxes on its charitable activities.

21) Analysis of net assets between funds

	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total 2024 £
Fixed assets	-	-	-	-
Cash and current Investments	382,661	740	284,173	667,574
Other current assets/(Liabilities)	(354)	-	-	(354)
Total	<u>382,307</u>	<u>740</u>	<u>284,173</u>	<u>667,220</u>

THROMBOSIS UK

Registered Charity No: 1090540

Company No: 4354472

**NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2024**

21) Analysis of net assets between funds (Continued)

	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total 2023 £
Fixed assets	-	-	-	-
Cash and current Investments	375,305	740	26,906	402,951
Other current assets/(Liabilities)	8,827	-	-	8,827
Total	384,132	740	26,906	411,778